Skip to content
DataLookout
Menu

NCT02605421

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 21 versions: 16 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Oct 1, 2026 to Oct 1, 2027
    • Eligibility criteria shortened, about 27 words
    • Study completion pushed from Dec 2026 to Dec 2028
    • Secondary endpoints: details revised at 2 of 3 entries
  2. Notable Primary completion date: Oct 1, 2025 to Oct 1, 2026
    • Study completion date: Dec 2025 to Dec 2026
    v20
  3. Notable Primary completion date: Jul 2024 to Oct 1, 2025
    • Study completion date: Jul 2025 to Dec 2025
    v18
  4. Notable Primary completion date: Jul 2023 to Jul 2024
    • Study completion date: Jul 2023 to Jul 2025
    v17
  5. Notable Primary completion date: Jul 2022 to Jul 2023v16
Show 10 earlier versionsHide 10 earlier versions
  1. Notable Primary completion date: Jul 2021 to Jul 2022v15
  2. Minor Site contact updatedv14
  3. Notable Primary completion date: Jul 2020 to Jul 2021v13
  4. Minor Primary completion date: Jan 2020 to Jul 2020
    • Study completion date: Jan 2023 to Jul 2023
    v12
  5. Notable Eligibility criteria revisedv11
  6. Notable Eligibility criteria expanded, about 67 wordsv9
  7. Minor Site contact updatedv5
  8. Minor Site contact updatedv4
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  10. Notable Start date: Jan 2016 to Jun 2016
    • Primary endpoint revised
    • Secondary endpoints revised (3)
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression Free Survival
Timeframe: 3 years from first PBSC infusion

Secondary (3)

Time to Engraftment
Relapse
Overall Survival

Arms and interventions

Patients Treated for NeuroblastomaExperimental

Consolidation course #1 consists of thiotepa and cyclophosphamide followed by a PBSC rescue. Consolidation course #2 consists of melphalan, etoposide and carboplatin followed by a second PBSC rescue. Post infusion, patients will receive Granulocyte-Colony Stimulating Factor beginning on Day 0 of each consolidation course.

Drugs: Thiotepa, Cyclophosphamide, Melphalan, Etoposide, Carboplatin

Biologicals: Autologous Stem Cell Infusion, Granulocyte colony stimulating factor

Sites

1 site in 1 country

  • Masonic Cancer Center, University of MinnesotaMinneapolis, Minnesota, United States